Increased large VLDL particles confer elevated cholesteryl ester transfer in diabetes

European Journal of Clinical Investigation

Volumn 45, Issue 1, 2015, Pages 36-44

  Dullaart, Robin P F ^a   de Vries, Rindert ^a   Kwakernaak, Arjan J ^a   Perton, Frank ^a   Dallinga Thie, Geesje M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cholesteryl ester transfer; Lipoprotein subfractions; Low density lipoproteins; Nuclear magnetic resonance spectroscopy; Type 2 diabetes mellitus; Very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTIDIABETIC AGENT; CETP PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; METABOLISM; PHYSIOLOGY;

CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 84921048165     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12377     Document Type: Article

References (36)

1. Dallinga-Thie GM, Dullaart RPF, van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007;18:251-7.
2. Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RPF. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovasc Ther 2011;29:e89-99.
3. Borggreve SE, de Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69.
4. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BH, van Tol A et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;54:3554-9.
5. Zeller M, Masson D, Farnier M, Lorgis L, Deckert V, Pais de Barros JP et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007;50:1948-55.
6. Kappelle PJ, Perton F, Hillege HL, Dallinga-Thie GM, Dullaart RPF. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study. Atherosclerosis 2011;217:249-52.
7. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991;88:2059-66.
8. Riemens S, van Tol A, Sluiter W, Dullaart RPF. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998;140:71-9.
9. de Vries R, Dikkeschei BD, Sluiter WJ, Dallinga-Thie GM, van Tol A, Dullaart RPF. Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus. Clin Lab 2012;58:1231-9.
10. Dullaart RPF, Groener JEM, Erkelens DW. Effect of the composition of very low and low density lipoproteins on the rate of cholesterylester transfer from high density lipoproteins in man, studied in vitro. Eur J Clin Invest 1987;17:241-8.
11. Eisenberg S. Preferential enrichment of large-sized very low density lipoprotein populations with transferred cholesteryl esters. J Lipid Res 1985;26:487-94.
12. Bagdade JDD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis 1993;104:69-77.
13. Bahanagar D, Durrington PN, Kumar S, Mackness MI, Boulton AJ. Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabet Med 1996;13:139-44.
14. Sutherland WH, Walker RJ, Lewis-Barned NJ, Pratt H, Tillman HC. Plasma cholesteryl ester transfer in patients with non-insulin dependent diabetes mellitus. Clin Chim Acta 1994;231:29-38.
15. Lottenberg SA, Lottenberg AM, Nunes VS, McPherson R, Quintão EC. Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates to lighter density lipoproteins in the fasting state and after a test meal are similar in Type II diabetics and normal controls. Atherosclerosis 1996;127:81-90.
16. Simera I, Moher D, Hoey J, Schulz KF, Altman DGA. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:14-22.
17. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70.
18. Channon KM, Clegg RJ, Bhatnagar D, Ishola M, Arrol S, Durrington PN. Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. Atherosclerosis 1990;80:217-26.
19. Selvin S. Statistical Analysis of Epidemiological Data. New York, NY: Oxford University Press; 1996.
20. Lu M, Lyden PD, Brott TG, Hamilton S, Broderick JP, Grotta JC. Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. J Neurosci Methods 2005;143:209-16.
21. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.
22. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62.
23. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010;59:1153-60.
24. Dullaart RPF, Constantinides A, Perton FG, van Leeuwen JJ, van Pelt JL, de Vries R et al. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. J Clin Endocrinol Metab 2011;96:1077-84.
25. Dullaart RPF, De Vries R, Scheek L, Borggreve SE, Van Gent T, Dallinga-Thie GM et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004;64:205-15.
26. Bouillet B, Gautier T, Blache D, Pais de Barros JP, Duvillard L, Petit JM et al. Glycation of apolipoprotein C1 impairs Its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes. Diabetes Care 2014;37:1148-56.
27. Adiels M, Borén J, Caslake MJ, Stewart P, Soro A, Westerbacka J et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1697-703.
28. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006;49:755-65.
29. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7.
30. Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004;110:1418-23.
31. Borggreve SE, Hillege HL, Dallinga-Thie GM, de Jong PE, Wolffenbuttel BH, Grobbee DE et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007;28:1012-8.
32. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010;121:366-74.
33. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009;120:2414-20.
34. Robins SJ, Lyass A, Brocia RW, Massaro JM, Vasan RS. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis 2013;228:230-6.
35. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012;125:2469-78.
36. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Stroes ES, Kastelein JJ et al. Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. Clin Chem 2010;56:789-98.